Bal Pharma Limited (BOM:524824)

India · Delayed Price · Currency is INR

107.47

+1.12 (1.05%)

At close: Sep 11, 2026

Market Cap	1.71B +21.4%
Revenue (ttm)	3.34B +13.5%
Net Income	72.07M +0.7%
EPS	4.50 -1.7%
Shares Out	15.92M
PE Ratio	23.87
Forward PE	n/a
Dividend	1.20 (1.36%)
Ex-Dividend Date	Sep 17, 2026

Volume	21,751
Open	106.42
Previous Close	106.35
Day's Range	104.80 - 114.84
52-Week Range	59.69 - 124.68
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2026

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic p... [Read more]

Industry Pharmaceutical Preparations

Founded 1987

Employees 939

Stock Exchange Bombay Stock Exchange

Ticker Symbol 524824

Full Company Profile

Financial Performance

In fiscal year 2026, Bal Pharma's revenue was 3.12 billion, an increase of 2.83% compared to the previous year's 3.03 billion. Earnings were 62.84 million, a decrease of -12.91%.

Financial Statements